The TROP-2 targeted therapy market presents key opportunities driven by rising cancer prevalence, particularly in challenging tumor types. Growth is supported by advancements in precision medicine, ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab ...

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the ...

Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether ...

Background Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially overexpressed ...

Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This ...

Researchers from Duality Biologics (Suzhou) Co. Ltd. presented preclinical data for a novel Trop-2-targeting antibody-drug conjugate (ADC), DB-1305, being developed for the treatment of solid tumors.

*Because of the small number of events (deaths and progressions) in the G1 EEC category, the confidence interval was not reliable.